Lung cancers with EGFR or ALK activating mutations generally acquire resistance to inhibitors targeting these proteins within 1 year due to secondary mutations that render the drugs ineffective or dysregulation of alternative RTK pathways5, 47. The gene discussed is ALK; the disease is lung carcinoma.